Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2017 1
2019 2
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year
Filters applied: . Clear all
Page 1
Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.
Chan D, Binks S, Nicholas JM, Frost C, Cardoso MJ, Ourselin S, Wilkie D, Nicholas R, Chataway J. Chan D, et al. Lancet Neurol. 2017 Aug;16(8):591-600. doi: 10.1016/S1474-4422(17)30113-8. Epub 2017 Jun 7. Lancet Neurol. 2017. PMID: 28600189 Free PMC article. Clinical Trial.
Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis.
Eshaghi A, Kievit RA, Prados F, Sudre CH, Nicholas J, Cardoso MJ, Chan D, Nicholas R, Ourselin S, Greenwood J, Thompson AJ, Alexander DC, Barkhof F, Chataway J, Ciccarelli O. Eshaghi A, et al. Proc Natl Acad Sci U S A. 2019 May 28;116(22):11020-11027. doi: 10.1073/pnas.1818978116. Epub 2019 May 9. Proc Natl Acad Sci U S A. 2019. PMID: 31072935 Free PMC article.
When we deconstructed the total treatment effect into indirect effects, which were mediated by brain atrophy, and direct effects, simvastatin had a direct effect (independent of serum cholesterol) on both the EDSS, which explained 69% of the overall treatment effect on EDSS, and …
When we deconstructed the total treatment effect into indirect effects, which were mediated by brain atrophy, and direct effects, simvastati …
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, Anderson V, Bangham CR, Clegg S, Nielsen C, Fox NC, Wilkie D, Nicholas JM, Calder VL, Greenwood J, Frost C, Nicholas R. Chataway J, et al. Lancet. 2014 Jun 28;383(9936):2213-21. doi: 10.1016/S0140-6736(13)62242-4. Epub 2014 Mar 19. Lancet. 2014. PMID: 24655729 Free article. Clinical Trial.
Simvastatin in patients with progressive multiple sclerosis--Authors' reply.
Chataway J; MS-STAT investigators. Chataway J, et al. Lancet. 2014 Sep 13;384(9947):952-3. doi: 10.1016/S0140-6736(14)61622-6. Lancet. 2014. PMID: 25220966 No abstract available.
Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin.
Lanzillo R, Moccia M, Russo CV, Carotenuto A, Nozzolillo A, Petruzzo M, Palladino R, Chataway J, Brescia Morra V. Lanzillo R, et al. Mult Scler Relat Disord. 2019 Feb;28:193-196. doi: 10.1016/j.msard.2018.12.042. Epub 2019 Jan 2. Mult Scler Relat Disord. 2019. PMID: 30623857 Free article. Clinical Trial.
Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England.
Palladino R, Marrie RA, Majeed A, Chataway J. Palladino R, et al. JAMA Neurol. 2020 Jul 1;77(7):820-828. doi: 10.1001/jamaneurol.2020.0664. JAMA Neurol. 2020. PMID: 32364569 Free PMC article.
Mortality risk was also higher for women than men. Treatment with lipid-lowering medications (mainly statins) was associated with lower mortality rates among people with MS. ...
Mortality risk was also higher for women than men. Treatment with lipid-lowering medications (mainly statins) was associated with low …
Feedback